A retrospective study for ALK positive Lung Cancer - The Clinical Benefits of Sequential Therapy using Crizotinib followed by Alectinib in Clinical Practice: A Multicenter Retrospective Study. - (WJOG9516L)
Not Applicable
- Conditions
- on-small-cell lung cancer (NSCLC)
- Registration Number
- JPRN-UMIN000028605
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 700
Inclusion Criteria
Not provided
Exclusion Criteria
No prior exposure of ceritinib before crizotinib or alectinib, regardless of clinical trial or practice.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method